KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Capital Employed: 2010-2025

Historic Return on Capital Employed for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to 0.08%.

  • Alnylam Pharmaceuticals' Return on Capital Employed rose 15.00% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 15.00%. This contributed to the annual value of -0.06% for FY2024, which is 4.00% up from last year.
  • Alnylam Pharmaceuticals' Return on Capital Employed amounted to 0.08% in Q3 2025, which was up 243.91% from -0.06% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.08% during Q3 2025, with a 5-year trough of -0.32% in Q2 2023.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Return on Capital Employed value was -0.06% (recorded in 2024), while the average stood at -0.09%.
  • In the last 5 years, Alnylam Pharmaceuticals' Return on Capital Employed skyrocketed by 35bps in 2024 and then declined by 9bps in 2025.
  • Alnylam Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.25% in 2021, then declined by 4bps to -0.28% in 2022, then grew by 18bps to -0.10% in 2023, then grew by 4bps to -0.06% in 2024, then increased by 15bps to 0.08% in 2025.
  • Its last three reported values are 0.08% in Q3 2025, -0.06% for Q2 2025, and -0.04% during Q1 2025.